AMPE Ampio Pharm

USD 0.04 0.00 0
Icon

Ampio Pharm (AMPE) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | OTC
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.04

0.00 (0.00)%

USD 0.51M

75.00

N/A

N/A

Icon

AMPE

Ampio Pharm (USD)
COMMON STOCK | OTC
USD 0.04
0.00 0
Take a Tour
stockTargetAdvisor

N/A

Average Analyst
Rating
stockTargetAdvisor

N/A

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.51M

N/A

USD 0.04

Ampio Pharm (AMPE) Stock Forecast

N/A

Based on the Ampio Pharm stock forecast from 0 analysts, the average analyst target price for Ampio Pharm is not available over the next 12 months. Ampio Pharm’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Ampio Pharm is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Ampio Pharm’s stock price was USD 0.04. Ampio Pharm’s stock price has changed by -55.56% over the past week, -69.23% over the past month and -99.16% over the last year.

No recent analyst target price found for Ampio Pharm
No recent average analyst rating found for Ampio Pharm

Company Overview Ampio Pharm

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuti...Read More

https://ampiopharma.com

9800 Mount Pyramid Court, Englewood, CO, United States, 80112

6

December

USD

USA

Adjusted Closing Price for Ampio Pharm (AMPE)

Loading...

Unadjusted Closing Price for Ampio Pharm (AMPE)

Loading...

Share Trading Volume for Ampio Pharm Shares

Loading...

Compare Performance of Ampio Pharm Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for AMPE

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Ampio Pharm (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF
Novo Nordisk A/S +1.50 (+1.14%) USD591.68B 45.03 4.92

ETFs Containing AMPE

Symbol Name AMPE's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Ampio Pharm (AMPE) Stock

Stock Target Advisor's fundamental analysis for Ampio Pharm's stock is Bearish.

Unfortunately we do not have enough data on AMPE's stock to indicate if its a good dividend stock.

Unfortunately we do not have enough data on AMPE's stock to indicate what its average analyst target is.

AMPE stock's Price/Earning ratio is 26.87. Our analysis grades AMPE stock's Price / Earning ratio at F. This means that AMPE stock's Price/Earning ratio is above 63% of the stocks in the Biotechnology sector in the OTC exchange. Based on this AMPE may be a overvalued for its sector.

The last closing price of AMPE's stock was USD 0.04.

The most recent market capitalization for AMPE is USD 0.51M.

Unfortunately we do not have enough analyst data on AMPE's stock to indicate whether its price will go up or not.

We can't find any ETFs which contains Ampio Pharm's stock.

As per our most recent records Ampio Pharm has 6 Employees.

Ampio Pharm's registered address is 9800 Mount Pyramid Court, Englewood, CO, United States, 80112. You can get more information about it from Ampio Pharm's website at https://ampiopharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...